TESAMORELIN 10mg Per Vial
TESAMORELIN 10mg Per Vial
Bacteriostatic (BAC) Water Included
No separate purchase required
Tesamorelin is one of the most clinically validated GHRH analogues in research - with a distinctive focus on visceral adipose tissue rather than total body weight.
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been extensively studied for its effects on the growth-hormone axis and, particularly, visceral adipose tissue. It is especially interesting because its research profile focuses on where fat is stored, rather than simply looking at total body weight.
Why is visceral fat important?
Visceral adipose tissue is fat stored within the abdominal cavity around internal organs. This differs from subcutaneous fat, which is located underneath the skin. Visceral adipose tissue is metabolically active and is therefore an important area of research into body composition and metabolic health.
Tesamorelin & Growth Hormone
Tesamorelin acts as a GHRH analogue. GHRH naturally stimulates the pituitary gland to release growth hormone, which subsequently influences downstream pathways including IGF-1. Clinical research has demonstrated measurable effects on the GH/IGF-1 axis.
Tesamorelin & Visceral Adipose Tissue
One of the most distinctive areas of Tesamorelin research is its relationship with visceral adipose tissue. Clinical studies have demonstrated reductions in visceral adipose tissue in specific populations. This has made Tesamorelin particularly interesting to researchers investigating abdominal fat distribution and metabolic physiology.
Tesamorelin & Body Composition
Research has shown that changes in visceral adipose tissue can occur without identical changes in every other fat compartment. This makes Tesamorelin useful for studying the difference between total body weight and body-fat distribution.
Tesamorelin & Liver Fat
Research has also investigated Tesamorelin in relation to ectopic fat, including liver fat. Clinical studies have reported reductions in liver fat alongside reductions in visceral adipose tissue in specific study populations.
Tesamorelin & Metabolic Research
Researchers have investigated Tesamorelin in relation to:
- Visceral adipose tissue
- Growth hormone
- IGF-1
- Body composition
- Liver fat
- Triglycerides
- Metabolic physiology
What makes Tesamorelin different?
-
GHRH analogue — Works through the growth-hormone-releasing pathway.
-
Visceral-fat research — One of its most established areas of research.
-
GH/IGF-1 signalling — Produces measurable downstream effects on the growth-hormone axis.
- Body-composition research — Particularly relevant to fat distribution.
Tesamorelin has approved pharmaceutical applications for specific indications. FDA prescribing information identifies EGRIFTA SV as tesamorelin for a specific indication involving excess abdominal fat in adults with HIV and lipodystrophy. Peptigen Tesamorelin 10 mg is nevertheless supplied as a laboratory research product.
Research Areas at a Glance
Visceral Fat • GHRH Signalling • Growth Hormone • IGF-1 • Body Composition • Liver Fat Research • Metabolic Research
Research Disclaimer: Information provided on this website is intended for scientific and educational purposes and should not be considered medical advice, a treatment recommendation, or guidance for personal use. Peptigen does not provide dosing, administration or reconstitution guidance for research compounds. Purchasers are responsible for ensuring that research materials are handled within an appropriate research environment and in accordance with applicable laws, regulations, laboratory protocols and safety requirements. Research use only.
Peptigen.
Quality. Research. Potential.